H.C. Wainwright downgraded Landos Biopharma (LABP) to Neutral from Buy with a price target of $20.42, down from $50, after the company announced a definitive agreement under which AbbVie (ABBV) is to acquire Landos.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LABP:
- This Biopharma Stock Outperformed MSTR and SMCI in March 2024
- Landos Biopharma’s Definitive Merger with AbbVie Subsidiary
- Landos Biopharma Inc trading resumes
- AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVR
